Blog Posts

Jun 27, 2025, 07:02

Elsevier Oncology – Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC

Elsevier Oncology posted on LinkedIn:

“From the Journal of Thoracic Oncology’s Editor’s Choice collection: compelling phase 1 data in NSCLC therapy.

Han B et al. present findings on Asandeutertinib’s safety, pharmacokinetics, and efficacy in advanced EGFR-mutated NSCLC.”

Title: Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study

Authors: Baohui Han, Jie Liu, Lin Wu, Yanqiu Zhao, Wei Zhang, Bolin Chen, Jianbo He, Jianhua Shi, Yanqing Liu, Zhe Zhang, Xiugui Chen, Yusheng Wu

Read The Full Article.

Elsevier Oncology - Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC

More posts featuring Lung Cancer.

Baohui Han Bolin Chen Elsevier Oncology Jianbo He Jianhua Shi Jie Liu Journal of Thoracic Oncology Lin Wu Lung cancer NSCLC Wei Zhang Xiugui Chen Yanqing Liu Yanqiu Zhao Yusheng Wu Zhe Zhang

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...